Colorectal cancer that has spread to the liver requires more than a standard “stage IV” treatment plan. In carefully selected patients, all visible disease can sometimes be removed or destroyed with curative intent. In others, systemic treatment can shrink disease enough to make a local treatment possible. When complete local treatment is not realistic, the priorities shift towards controlling the cancer, preserving liver function, preventing complications and maintaining quality of life.
The most important early question is therefore not simply “Which medicine should be used?” It is whether the liver metastases are resectable now, potentially resectable after treatment, suitable for thermal ablation or another local technique, or permanently unresectable. That decision should be made by a colorectal and hepatobiliary multidisciplinary team after reviewing high-quality imaging, pathology, tumour biology, the primary tumour and all sites of disease.
Colon cancer and rectal cancer share many systemic treatment principles, but they are not identical. A rectal primary may require pelvic MRI, radiotherapy, total neoadjuvant treatment or a different order of surgery. A symptomatic bowel tumour may also change the sequence. For these reasons, the liver plan and the bowel plan must be designed together.
This guide explains how specialists assess colorectal and rectal cancer with liver metastases, including liver MRI, molecular testing, conversion therapy, surgery, microwave or radiofrequency ablation, stereotactic radiotherapy and other liver-directed options. It also explains what medical records to send for a second opinion and how international treatment planning in Türkiye can be coordinated for patients from the United Kingdom, Ireland, the United States, Canada, Australia, New Zealand and English-speaking countries across Africa.
No online guide can determine whether an individual patient is suitable for surgery, ablation, transplantation, immunotherapy or a specific drug. Treatment recommendations and medicine approvals differ between countries and change over time. The final plan must be made by licensed clinicians who have reviewed the complete case.
Patients with severe or increasing abdominal pain, persistent vomiting, abdominal swelling, jaundice, confusion, fever during anticancer treatment, heavy rectal bleeding, inability to pass stool or gas, sudden weakness, breathlessness or signs of dehydration should seek urgent medical care where they are. An international records review or flight must not delay emergency assessment.
Colorectal liver metastases are deposits of colon or rectal cancer cells in the liver. They are not primary liver cancer. Even though the lesions are located in the liver, their pathology and treatment are based on their colorectal origin.
Colorectal cancer begins in the colon or rectum and is often called bowel cancer. When it spreads to the liver, it may also be described as liver secondaries or secondary cancer in the liver.
The liver is a common site of colorectal cancer spread because blood from much of the bowel travels through the portal circulation to the liver. Liver metastases may be discovered at the same time as the bowel tumour or after treatment for an earlier-stage cancer.
The terms commonly used are:
This timing provides useful information but does not determine treatment by itself. A patient with synchronous disease may still be considered for curative-intent treatment, while a patient with a single later lesion may still have biologically aggressive disease. The team also considers how quickly the cancer has developed, whether disease exists outside the liver, molecular findings, the patient’s response to previous treatment and whether every known site can be controlled.
Liver metastases may be:
These patterns create different treatment possibilities. The number and size of lesions matter, but modern resectability is not defined by a simple maximum number of tumours.
Stage IV means that colorectal cancer has spread to a distant organ or site. It does not mean that every patient has the same prognosis or the same treatment goal.
When all known cancer can be removed or destroyed while leaving enough functioning liver and controlling the primary tumour, the team may pursue a curative-intent strategy. The word “intent” is important: recurrence after liver treatment is common, and no responsible centre can guarantee cure.
A curative-intent plan may use one or more of the following:
The objective is not merely to reduce the amount of cancer in the liver. It is to achieve durable control of all known disease sites with an acceptable safety profile. Removing some liver lesions while knowingly leaving uncontrolled cancer elsewhere is usually not a curative strategy.
When complete local clearance is not possible, treatment may still produce meaningful control, relieve symptoms and extend life. Systemic therapy remains central because it treats visible and microscopic cancer throughout the body.
Colon and rectal cancers are both colorectal cancers, but the location of the primary tumour can change staging, local treatment and sequencing.
For a colon primary, the team evaluates whether the bowel tumour is causing obstruction, perforation, significant bleeding or another urgent problem. If it is asymptomatic and the liver disease is not immediately resectable, systemic treatment often begins before removing the colon tumour. Routine removal of an asymptomatic primary does not automatically improve outcomes in permanently unresectable metastatic disease and can delay systemic therapy.
If both the colon tumour and liver metastases are suitable for local treatment, the team may consider simultaneous or staged surgery. A straightforward colectomy combined with a limited liver resection or ablation may be reasonable in a fit patient. Combining a difficult colorectal operation with a major hepatectomy generally requires greater caution.
Rectal cancer requires dedicated pelvic assessment. Pelvic MRI helps define the tumour’s relationship to the mesorectal fascia, sphincter complex, lymph nodes and nearby organs. The rectal plan may include systemic chemotherapy, short-course or long-course radiotherapy, total neoadjuvant treatment, total mesorectal excision or, in selected patients with a complete clinical response, an intensive organ-preservation programme.
When rectal cancer and important liver disease are present together, the order of treatment can be complex. A liver-first sequence may be considered when the liver disease is the immediate threat or could become unresectable during a prolonged pelvic treatment pathway. In other cases, treatment of the rectal primary comes first. The correct sequence depends on symptoms, liver anatomy, pelvic stage, response and the complexity of each operation.
Before recommending a drug or procedure, the multidisciplinary team should answer four connected questions:
The answer can change. A patient initially described as unresectable may become resectable after expert review or a favourable response. A patient who appears technically resectable may be advised to start systemic treatment because imaging suggests aggressive biology or disease outside the liver. Reassessment is part of the plan, not an afterthought.
Treatment planning should begin with a review of the original diagnosis, not just the latest scan. Important documents include the colonoscopy report, pathology, operation notes, previous systemic treatment, radiotherapy records, molecular tests and serial imaging.
The pathology report should confirm the tumour type and provide relevant features. If the original diagnosis, tumour origin or biomarker result is uncertain, a specialist gastrointestinal pathologist may review the slides or paraffin blocks.
Pathology review is particularly valuable when:
The team reviews whether the entire colon has been examined, where the primary tumour is located, whether it is obstructing the lumen and whether synchronous bowel lesions are present. If a complete colonoscopy was impossible because of obstruction, an alternative assessment or later completion colonoscopy may be needed.
For rectal cancer, the distance from the anal verge, relationship to the sphincter and pelvic stage must be documented. A generic statement such as “colorectal cancer” is not enough for sequencing.
Contrast-enhanced CT of the chest, abdomen and pelvis is a standard part of metastatic staging. It helps assess the liver, lungs, lymph nodes, peritoneum, primary tumour and other organs. The imaging files themselves are more useful for a second opinion than a written report alone.
Liver MRI with an appropriate contrast protocol can define the number, size and location of lesions more accurately than CT in many patients, particularly when lesions are small, treatment-altered or potentially suitable for surgery or ablation. Hepatobiliary contrast and diffusion-weighted sequences may help identify lesions that are difficult to see on other studies.
High-quality hepatobiliary-contrast liver MRI should generally be obtained for every patient being considered for resection, ablation or another curative-intent liver treatment, and when CT findings are atypical or indeterminate. It is particularly important when:
For a rectal primary, pelvic MRI provides local staging that liver imaging cannot. It helps the team plan radiotherapy, surgery and the order of pelvic and liver treatment.
PET-CT may be useful when curative local treatment is contemplated and an unexpected extrahepatic site would change the plan, or when conventional imaging is inconclusive. It does not replace liver MRI, diagnostic contrast CT or pelvic MRI. Small lesions, mucinous tumours and treatment-altered disease may show limited uptake.
Assessment commonly includes:
CEA can support monitoring but cannot confirm or exclude progression by itself. Some colorectal cancers produce little or no CEA.
No. A patient with confirmed colorectal adenocarcinoma and liver lesions that are radiologically typical may not need a liver biopsy, especially when the lesions are technically resectable and the diagnosis is clear.
An unnecessary biopsy can cause bleeding, infection or delay. It can also be non-diagnostic. The decision should be made by the treating multidisciplinary team rather than assumed from a general checklist.
When the primary pathology and imaging are convincing, percutaneous biopsy of a potentially resectable liver metastasis is generally avoided unless it would change management, because it adds bleeding risk and a rare risk of needle-tract seeding.
A biopsy may be useful when:
The best biopsy target is not automatically the liver. A lymph node, lung lesion or other accessible site may provide the required information with less risk. The interventional radiologist, pathologist and oncologist should agree on the target and the tests required before tissue is collected.
If molecular testing is the main purpose, archived tissue or a blood-based liquid biopsy may sometimes answer the question. A negative plasma result can be false when little tumour DNA is circulating, so tissue testing may still be needed when the result would change care.
Resectability is not determined by a universal limit on lesion number or size. Modern assessment asks whether all clinically important disease can be removed or destroyed while leaving a safe, functioning liver.
The liver team evaluates whether treatment can preserve:
The anticipated remnant depends on liver health. A normal liver may tolerate a smaller remnant than a liver affected by prolonged chemotherapy, steatosis, fibrosis, cholestasis or cirrhosis. Volumetry may be combined with functional tests when a major operation is planned.
An operation can be technically possible but oncologically unwise. The team considers:
Limited, controllable disease outside the liver is not always an absolute exclusion, but unresectable or rapidly progressive extrahepatic disease usually argues against a curative liver operation.
The team also assesses cardiopulmonary health, frailty, nutrition, kidney function, diabetes, previous operations, current infection, performance status and the patient’s ability to recover from one or more major procedures.
Resectability can vary between centres because expertise in parenchymal-sparing surgery, two-stage procedures, ablation and vascular reconstruction differs. A statement of “inoperable” should ideally be reviewed by a hepatobiliary surgeon who regularly treats colorectal liver metastases, particularly when disease is confined to or dominated by the liver.
The purpose of a second opinion is not to force an operation. It is to establish whether the full range of safe options has been considered. Recmed’s guide to a cancer second opinion in Türkiye explains how to prepare imaging and medical records for review.
A complete plan may require input from:
The tumour board should not merely list available treatments. It should document:
A defined reassessment date is essential in conversion therapy. Once complete local treatment becomes possible, continuing chemotherapy can expose the liver to additional injury and may allow the surgical window to close.
Molecular testing can directly influence treatment selection. It can determine whether immunotherapy, an EGFR-directed treatment, a BRAF-directed combination or another targeted option is relevant. It can also identify inherited cancer risk.
Every colorectal cancer should undergo validated MMR/MSI assessment. In metastatic disease, the result can determine first-line immunotherapy and can trigger Lynch-syndrome evaluation.
The required panel depends on the disease setting, available tissue, local guidelines and treatment access. Commonly relevant assessments include:
Not every alteration is actionable, and a report that lists a drug does not prove that the drug is appropriate. The oncologist must interpret the finding in relation to the exact tumour type, line of treatment, evidence, medicine label and country of care.
Mismatch-repair deficiency, or dMMR, and high microsatellite instability, or MSI-H, identify a biologically distinct subgroup. For unresectable or metastatic dMMR/MSI-H colorectal cancer, immune-checkpoint therapy is a first-line standard. Current ESMO guidance prefers nivolumab plus ipilimumab, with pembrolizumab a strong alternative when the doublet is unsuitable; approvals and age indications vary by country. These findings can also raise the possibility of Lynch syndrome.
MMR may be assessed by immunohistochemistry, while MSI can be evaluated by PCR or a validated NGS assay. A technically adequate result is important. When the pattern suggests Lynch syndrome, the patient may need genetic counselling and germline testing because not every abnormal result is inherited.
An MSI-H or dMMR result does not itself determine whether liver surgery or ablation is appropriate. Local-treatment decisions still depend on anatomy, extent, response and patient fitness. Immunotherapy may profoundly alter the sequencing in an unresectable case and should be discussed by the multidisciplinary team.
For a broader explanation, see Recmed’s guide to MSI/MMR testing and immunotherapy planning.
Extended RAS status helps determine whether an EGFR-directed antibody is likely to be useful. A RAS mutation predicts lack of benefit from cetuximab or panitumumab, and anti-EGFR therapy is not recommended for RAS-mutant disease.
For a treatment-naïve, left-sided, RAS wild-type, microsatellite-stable tumour, an EGFR-directed antibody combined with an appropriate chemotherapy backbone may be favoured when a deep response is important. For right-sided RAS-wild-type MSS or pMMR disease, chemotherapy plus anti-VEGF treatment is normally preferred first line; selected response-oriented conversion use of anti-EGFR treatment requires expert multidisciplinary review. These principles should not be applied without clinical context; performance status, treatment goal, molecular profile, toxicity, prior therapy and regional approvals still matter.
The primary tumour’s side should therefore appear in the treatment summary:
BRAF V600E is associated with a distinct disease biology and can change treatment selection. ESMO 2026 recommends first-line encorafenib plus cetuximab plus fluoropyrimidine chemotherapy for BRAF V600E metastatic colorectal cancer. Approved backbones, reimbursement and treatment lines differ by jurisdiction. Non-V600 BRAF alterations are biologically heterogeneous and must not automatically be managed as BRAF V600E.
A treatment proposal should not present any one treatment line as universally applicable. The clinic should state the evidence-based option, its regulatory status in the country of treatment and whether the medicine is included in the quoted cost.
HER2 amplification or overexpression can be clinically relevant in a subset of metastatic colorectal cancers, particularly within RAS wild-type disease. HER2 positivity should be established using an accepted colorectal-cancer assay and scoring algorithm; a breast-cancer score or the phrase “HER2 detected” is not automatically sufficient to select treatment.
HER2-directed options may be available after prior therapy in an appropriate molecular setting, subject to local approval. HER2 status can also influence how the team interprets resistance to EGFR-directed treatment.
Selected patients may have a KRAS G12C alteration, an NTRK fusion or another rare finding with a matched treatment in a particular line of therapy. These findings are uncommon and are best evaluated through validated testing rather than broad claims that every patient will find a target.
Some alterations require an RNA-based assay or confirmation by another method. The molecular laboratory report should state the specimen, tumour content, platform, genes and alteration types assessed, assay limitations and clinical classification.
Tissue NGS can assess tumour DNA and, on some platforms, RNA. It has the advantage of confirmed tumour content and correlation with pathology, but the block may be old, small or depleted.
A plasma liquid biopsy examines circulating tumour DNA. It can be useful when tissue is unavailable, a procedure would be unsafe or a rapid molecular result is needed. However, some tumours release little DNA into the blood. A negative plasma result does not reliably exclude an alteration, and tissue may still be required.
The two methods are complementary. Recmed’s guide to NGS tumour profiling, tissue biopsy and liquid biopsy explains the practical differences.
MMR/MSI findings, age at diagnosis, multiple cancers and family history may support referral for genetic counselling. Germline testing differs from tumour profiling: it looks for inherited variants that may affect the patient and biological relatives.
The result can influence surveillance, risk-reducing strategies and family testing. It should be accompanied by appropriate counselling rather than delivered as an isolated laboratory finding.
Fluoropyrimidines can cause severe toxicity in patients with reduced dihydropyrimidine dehydrogenase, or DPD, activity. Pretreatment DPD testing is recommended or required in many jurisdictions. The European Medicines Agency supports genotype or phenotype testing, and 2026 United States fluoropyrimidine labels recommend DPYD variant testing unless treatment cannot be delayed. Complete deficiency generally requires avoidance; partial deficiency requires an individualised starting-dose reduction. A normal panel does not eliminate toxicity risk.
UGT1A1 testing may be considered in selected patients before irinotecan, particularly when a high dose is planned or clinical factors suggest greater risk. It is not a universal substitute for clinical monitoring.
Postoperative circulating tumour DNA is strongly prognostic, but it should not routinely determine treatment escalation or de-escalation outside a validated pathway or prospective trial, and it must not replace CT or MRI, CEA or clinical surveillance.
Once staging, biology and fitness have been reviewed, most cases fit one of four broad pathways. The category can change over time.
If all disease can be safely eradicated now, the team may recommend upfront local treatment or a short course of perioperative systemic therapy followed by reassessment. Surgery alone and surgery with perioperative chemotherapy are both accepted strategies in selected resectable cases. Evidence has not established a universal overall-survival advantage for perioperative chemotherapy in every patient.
The decision depends on recurrence risk, previous treatment, tumour biology, lesion burden, operative complexity and whether a period of systemic treatment would provide useful information about disease behaviour.
For technically suitable liver metastases under 3 cm, current ESMO guidance supports thermal ablation as a first local option and, in appropriately selected cases, favours it over resection. This does not apply automatically to every small lesion. A safe ablation margin, reliable imaging, distance from vulnerable bile ducts or bowel and local expertise are essential.
Some liver metastases cannot initially be cleared because of their relationship to critical vessels, inadequate future liver remnant, extensive bilobar distribution or the need to reduce tumour volume. Active systemic therapy may shrink or control disease enough to make resection or ablation possible.
This is conversion therapy, not indefinite palliative treatment. The plan should include:
When sufficient conversion has occurred, treatment should move promptly towards local clearance. Additional chemotherapy solely to make lesions disappear radiologically can increase liver injury and make operative localisation more difficult.
If all disease cannot be eradicated, systemic therapy is usually the foundation. The goal may be disease control, symptom relief, prevention of liver failure and preservation of function.
Selected patients with limited liver-dominant progression may also be considered for ablation, stereotactic radiotherapy, arterial treatment or another regional therapy at an expert centre. These approaches should have a defined purpose and should not be presented as routine replacements for effective systemic treatment.
Permanently unresectable liver-only disease with favourable biology may justify an early transplant-centre opinion. The eligibility criteria are strict, and most patients will not qualify.
Obstruction, perforation, uncontrolled bleeding or sepsis can override the preferred oncological sequence. Management may involve a stent, diverting stoma, resection, radiotherapy or another urgent procedure. The least disruptive safe option may be chosen so that systemic or liver treatment can begin or resume.
Systemic treatment reaches cancer cells in the liver and elsewhere. The regimen is selected according to the goal, molecular profile, tumour side, previous therapy, symptoms, organ function, fitness and access.
Common backbones combine a fluoropyrimidine with oxaliplatin or irinotecan. A three-drug backbone may be considered for selected fit patients when a high response rate is important, but it increases toxicity and is not appropriate for everyone. An oral fluoropyrimidine may be used instead of an infused regimen in some settings, while other patients need dose modification or a less intensive regimen.
The treating oncologist should explain:
A VEGF-directed antibody may be combined with chemotherapy in many microsatellite-stable metastatic settings. It can impair wound healing, raise blood pressure and increase the risks of bleeding, clotting and bowel perforation. Timing around an operation must therefore be planned carefully, and the surgeon should know the date of the last dose.
An EGFR-directed antibody may be used for an appropriate RAS wild-type tumour, with primary tumour location influencing first-line selection. Potential toxicities include acne-like rash, diarrhoea, magnesium loss and infusion reactions. Proactive skin care and laboratory monitoring are important.
When maximal shrinkage is sought before possible liver surgery, tumour biology and sidedness can influence which biologic partner is chosen. The decision belongs in the conversion plan rather than being based on a single mutation result in isolation.
For unresectable or metastatic MSI-H or dMMR colorectal cancer, immune-checkpoint therapy is a first-line standard. Current ESMO guidance prefers nivolumab plus ipilimumab, with pembrolizumab a strong alternative when the doublet is unsuitable. Approvals and age indications vary by country.
Immune-related complications can affect the bowel, lungs, liver, endocrine organs, heart, nervous system, kidneys, skin and other tissues. New diarrhoea, breathlessness, jaundice, severe fatigue, headache, weakness or confusion requires prompt clinical assessment. Side effects can occur during treatment or after it has ended.
BRAF V600E, HER2, KRAS G12C, NTRK and other selected alterations may support targeted treatment in the correct clinical context. The exact medicine combination and treatment line must be checked against the current local label and guideline.
After progression, treatment choice depends on all prior treatments, residual toxicity, molecular results, disease tempo and available trials. Later-line oral agents, targeted combinations, immunotherapy for the appropriate biomarker and regional or local treatment may be considered.
The order matters. A molecularly matched option should not be overlooked because the report was reviewed too late, but an unvalidated match should not displace a proven standard treatment.
Liver resection remains a central curative-intent treatment for colorectal liver metastases that are not better managed by ablation and can be completely cleared with an adequate remnant.
Where oncologically and technically sound, surgeons try to remove the tumours while preserving as much healthy liver as possible. This may reduce the immediate risk of liver failure and preserve options if recurrence later requires repeat surgery or ablation.
An operation may include wedge resections, segmental resections, a formal lobar resection or a combination. The term “minor” or “major” refers to the extent of liver removed, not to the seriousness of the cancer.
The goal is complete removal with a microscopically negative margin. A modern plan does not always require a very wide margin, but a tumour should not knowingly be left behind. The achievable margin must be considered together with vascular anatomy, liver preservation and tumour biology.
Treating the bowel primary and liver metastases in one operation can reduce the number of admissions and avoid an interval between procedures. This approach is most suitable when the colorectal operation and liver treatment are both limited and the patient is fit.
Potential disadvantages include a longer operation, the cumulative risk of complications and a more difficult recovery. Routine combination of complex rectal surgery with major liver resection is generally approached cautiously.
A staged plan separates the colorectal and liver operations. It may be safer when either procedure is complex, when recovery from one operation is needed before the next or when the disease biology should be observed between steps.
The possible sequences are:
There is no universal best sequence. The written plan should explain why the chosen order is safest for the individual case.
If the future liver remnant would be too small, portal vein embolisation can redirect portal blood flow and stimulate growth of the liver that will remain. After adequate growth and functional assessment, the planned resection may proceed.
This is an established adjunct, but not every patient reaches the second step. Disease can progress, or the remnant may not grow sufficiently. Risks include bleeding, infection, portal-vein thrombosis and non-target embolisation.
Extensive disease in both liver lobes may require two operations. The first clears disease from the intended future remnant, often followed by portal vein embolisation. The second removes the remaining tumour-bearing liver after the remnant has grown and disease control has been confirmed.
This is a demanding pathway with a risk that progression prevents completion. It should be undertaken at a centre experienced in complex liver surgery and in integrating systemic treatment.
Liver venous deprivation is an evolving method designed to generate more rapid or robust remnant growth by combining portal and hepatic venous approaches. Evidence and availability are less mature than for standard portal vein embolisation.
ALPPS combines liver partition and portal-vein interruption to stimulate rapid growth before a second operation. It can increase completion in selected extensive disease but carries substantial complication and mortality risk. Rapid volume gain may overstate functional recovery. ALPPS is not a routine first choice and should be reserved for carefully selected patients in an expert centre, sometimes after another hypertrophy strategy has failed.
Oxaliplatin and irinotecan can produce different patterns of liver injury, and prolonged systemic treatment may impair regeneration or increase operative risk. The liver surgeon needs the exact regimen, dose dates, cumulative exposure and laboratory trend.
This is another reason not to continue conversion chemotherapy without a scheduled resectability review.
A lesion that disappears on CT after systemic treatment is not necessarily eradicated. Residual microscopic or viable disease may remain.
Before treatment, high-quality imaging should map every lesion. After response, hepatobiliary-contrast MRI and intraoperative ultrasound may help locate treatment sites. The team should decide whether the original area will be resected, ablated or closely followed rather than assuming that radiological disappearance equals cure.
Recurrence does not always end the possibility of local treatment. Selected patients with limited recurrent liver or lung disease may undergo repeat resection, ablation or stereotactic radiotherapy after another complete review.
The feasibility of repeat treatment is one reason to preserve healthy liver tissue during the first procedure whenever safely possible.
Thermal ablation destroys a metastasis by placing one or more probes into or around it and producing a controlled zone of heat. It can be performed through the skin, laparoscopically or during open surgery.
The two most established thermal methods are:
Both can be effective in appropriately selected small colorectal liver metastases. Microwave systems can create larger and faster ablation zones and may be less affected by heat loss near blood vessels, while radiofrequency ablation has a longer-established evidence base and may be suitable in other anatomical situations. No technique is universally best.
Ablation is most reliable when:
Current ESMO guidance and randomised evidence support thermal ablation as a curative-intent alternative, and for technically suitable lesions under 3 cm it may be preferred over resection because it can preserve healthy liver tissue and reduce complications. These results came from carefully selected expert-centre patients and must not be extrapolated to larger, poorly positioned or incompletely visualised lesions.
The visible tumour is not the only area that needs treatment. The operator aims to create a surrounding zone of destroyed tissue. At least 5 mm is generally required, while approximately 10 mm is preferred where safely achievable.
If a sufficient margin cannot be created because of a central bile duct, bowel, diaphragm or other critical structure, surgery, stereotactic radiotherapy or another strategy may provide better local control.
Some patients have a mixture of lesions. The surgeon may remove a larger or centrally placed tumour and ablate smaller lesions in the opposite lobe. This can achieve complete local treatment while preserving more healthy liver tissue than a major bilateral resection.
Risks can include:
The written proposal should state whether ablation will be percutaneous, laparoscopic or open; which lesions will be treated; the intended margin; the imaging-guidance method; and what would cause the team to change strategy during the procedure.
The choice is not a contest between two technologies. It is a lesion-by-lesion decision within a complete cancer plan.
Thermal ablation may be attractive because it:
Surgery may be preferred when:
For suitable small lesions, ablation is no longer accurately described only as a fallback for patients who cannot have surgery. Conversely, it should not be advertised as replacing surgery for all colorectal liver metastases.
Stereotactic body radiotherapy delivers a highly focused radiation dose over a small number of sessions. In the United Kingdom and some other regions, the term stereotactic ablative radiotherapy, or SABR, is commonly used.
SBRT may be considered when:
The radiation oncologist evaluates tumour motion with breathing and the proximity of the stomach, bowel, duodenum, central bile ducts, kidneys, chest wall and other organs. Fiducial markers or specialised motion-management methods may be required.
Potential side effects include fatigue, nausea, temporary liver-test abnormalities and discomfort. Less common but serious risks include liver injury, bile-duct stenosis, ulceration, bleeding or bowel damage. The dose, number of treatments and expected likelihood of local control should be individualised.
SBRT is a valuable non-invasive local option, but it should not automatically replace resection or technically suitable thermal ablation.
Arterial or regional treatments can intensify therapy within the liver. Their role is narrower than surgery or ablation, and they are not routine first-line substitutes for systemic treatment.
Selective internal radiation therapy, also called transarterial radioembolisation or Y-90 treatment, delivers radioactive microspheres through the hepatic artery.
Adding Y-90 routinely to first-line chemotherapy has not produced an overall-survival benefit in large trials. In later-line liver-dominant disease, it can improve control within the liver in selected patients, but pivotal randomised trials have not shown an overall-survival improvement.
It may be considered when:
Y-90 can also be used in a specialised “radiation lobectomy” strategy to control tumour in one lobe while stimulating growth of the other. Growth is generally slower than after portal vein embolisation, so the method is not interchangeable in every surgical timeline.
Risks include fatigue, pain, nausea, non-target gastrointestinal ulceration, biliary injury, radiation pneumonitis and radioembolisation-induced liver disease. Mapping angiography, shunt assessment and individual dosimetry are essential.
A hepatic arterial infusion, or HAI, pump delivers chemotherapy into the hepatic artery and is generally combined with systemic treatment to address disease elsewhere. High hepatic response and conversion rates have been reported in specialist programmes, but the procedure requires surgery, pump expertise and intensive monitoring.
HAI may be considered for selected liver-only or liver-dominant disease in a mature multidisciplinary programme. It is not a routine universal standard, and randomised evidence has not shown that every postoperative patient benefits.
Potential complications include pump or catheter infection, migration, thrombosis, arterial injury, non-target perfusion, stomach or duodenal ulceration, chemical hepatitis and biliary sclerosis. Concurrent bevacizumab with floxuridine HAI is generally avoided because it increases biliary toxicity. Treatment should not be offered without an experienced multidisciplinary pathway encompassing pump surgery, nuclear medicine, oncology and specialist nursing.
Transarterial chemoembolisation, including irinotecan-loaded bead treatment, has been used for selected patients with refractory, liver-dominant colorectal cancer. Evidence is weaker and less consistent than for established systemic therapy, resection or small-lesion thermal ablation.
It may have a salvage or trial role in a patient with preserved liver function and acceptable portal flow. Post-embolisation pain, fever, nausea and fatigue are common. Liver abscess, biliary injury, cholecystitis, arterial damage, non-target bowel injury and liver failure are less common but important risks.
Percutaneous hepatic perfusion with melphalan is not an established standard for colorectal liver metastases. Current evidence is limited, and its regulatory approval in some settings applies to another cancer type. For colorectal metastases it should be considered research-only unless a future guideline and national approval state otherwise.
Liver transplantation has moved from an experimental concept to a guideline-supported curative-intent option for a very small, biologically favourable group with permanently unresectable liver-only colorectal metastases. It is not routine treatment.
Current ESMO criteria provide a useful benchmark rather than universal programme rules. They include:
Criteria differ between programmes, and meeting a checklist does not guarantee acceptance. Donor availability, transplant policy and competing organ-allocation priorities are central.
Transplantation involves major surgery, lifelong immunosuppression and substantial risks, including perioperative death, graft failure, rejection, infection, vascular or biliary complications, kidney and metabolic toxicity and cancer recurrence. Recurrence remains possible and often requires further systemic or local treatment.
Patients who might meet these conditions should be referred early to a recognised transplant-oncology programme rather than after all treatment options and physical reserve have been exhausted.
For clearly resectable liver metastases, both surgery alone and surgery with perioperative chemotherapy can be reasonable. Perioperative treatment may improve progression-related outcomes in selected patients, but it has not demonstrated a universal overall-survival advantage after complete resection.
Reasons to consider systemic treatment before surgery include:
Reasons to proceed directly to local treatment can include easily resectable or ablatable disease, favourable biology, risk of chemotherapy-associated liver injury, prior oxaliplatin exposure or concern that treatment could make small lesions disappear radiologically.
An EGFR-directed antibody should not be added to perioperative chemotherapy for clearly resectable RAS wild-type liver metastases. Randomised evidence found worse outcomes with this strategy. That warning is different from the use of an EGFR-directed regimen to achieve conversion in initially unresectable, left-sided, RAS/BRAF wild-type disease.
When a VEGF-directed medicine is used, the operation must be timed around wound-healing and bleeding risk. The required interval should follow the medicine label and the treating centre’s surgical protocol.
The primary tumour should be treated according to symptoms, local risk and the overall metastatic plan—not simply because it exists.
When the primary is not causing obstruction, perforation or significant bleeding and the metastases are permanently unresectable, initial systemic treatment is often preferred. Routine prophylactic removal of the primary has not shown a survival advantage and can cause complications or delay systemic treatment.
Obstruction may require:
The choice depends on tumour location, perforation risk, curative intent, available expertise and the planned systemic or liver treatment.
Significant bleeding may be managed by endoscopy, radiotherapy, embolisation or surgery depending on the site and severity. Perforation or uncontrolled sepsis generally requires urgent local treatment.
An asymptomatic rectal primary in non-curable metastatic disease may initially be managed with systemic therapy. Pelvic radiotherapy or surgery can be used for bleeding, pain, threatened obstruction or a defined curative sequence.
For potentially curative metastatic rectal cancer, high-quality pelvic MRI and a specialist rectal-cancer tumour board should integrate pelvic radiotherapy, systemic treatment, total mesorectal excision and liver treatment. A standard localised rectal-cancer template should not be applied automatically.
Peritoneal metastases are cancer deposits on the abdominal lining. They are different from liver metastases and require a separate assessment.
Selected patients with limited, completely removable peritoneal disease may be considered for cytoreductive surgery at an experienced centre. The addition of oxaliplatin-based heated intraperitoneal chemotherapy, or HIPEC, is not routinely recommended based on current randomised evidence.
HIPEC does not treat liver metastases. A patient with both peritoneal and liver disease requires particularly careful assessment because the feasibility and value of complete local treatment differ from a liver-only case.
Recmed’s HIPEC information page should be read as a separate procedure guide, not as an alternative to liver surgery or ablation.
Conversion treatment has value only when response is measured and the case returns to the liver tumour board on time.
Monitoring may include:
In a potentially resectable case, imaging is commonly repeated after approximately 8 to 12 weeks, although a faster or slower schedule may be appropriate. The liver surgeon and radiologist should compare the original and current images, not just read the latest report.
The response categories should include more than “smaller” or “stable.” The team should state whether:
If the disease progresses despite systemic treatment, the team must reconsider whether the biology is compatible with a major curative-intent operation. If a deep response makes local treatment possible, referral should not be postponed until every planned chemotherapy cycle is completed.
After liver resection or ablation, follow-up generally includes clinical review, CEA, cross-sectional imaging and surveillance of the colon or rectum. The schedule depends on the original stage, procedure, systemic treatment, recurrence risk and applicable national guidelines.
Follow-up aims to detect:
Recurrence is common, but it is not always untreatable. A new multidisciplinary review may consider repeat surgery, ablation, SBRT, systemic treatment or a clinical trial.
Population survival statistics cannot predict an individual outcome. Prognosis depends on the ability to clear all disease, tumour biology, extrahepatic spread, response, disease-free interval, CEA, molecular profile, physical health and whether the proposed multistep treatment can be completed.
Every patient should receive a written emergency plan with contact numbers and instructions that remain usable after returning home.
Fluorouracil and capecitabine can cause diarrhoea, mouth inflammation, low blood counts, hand-foot syndrome and, less commonly, serious heart or neurological toxicity. Severe early toxicity can be associated with DPD deficiency and is a medical emergency.
Urgent assessment is required for severe diarrhoea, inability to drink, chest pain, fainting, confusion, severe mouth ulcers, rapidly worsening weakness or fever. Suspected overdose or early-onset severe or life-threatening fluoropyrimidine toxicity requires emergency oncology or toxicology assessment. Uridine triacetate is most effective when started within 96 hours; benefit after 96 hours is not established.
Oxaliplatin can cause cold-triggered nerve symptoms, cumulative numbness or pain, allergic reactions and liver sinusoidal injury. New difficulty breathing or swelling during an infusion requires immediate attention. Progressive neuropathy should be reported before it becomes disabling.
Irinotecan can cause early cholinergic symptoms, delayed diarrhoea and severe neutropenia. The clinic should provide exact instructions for diarrhoea management. Any fever, dehydration, persistent diarrhoea or marked weakness requires urgent assessment.
Possible serious effects include bleeding, clotting, high blood pressure, proteinuria, impaired wound healing and bowel perforation. Any sudden severe abdominal pain, heavy bleeding, chest pain, one-sided weakness or painful swelling in a leg requires emergency care.
Common effects include acne-like rash, dry or cracked skin, diarrhoea and low magnesium. Severe infection, eye pain, breathing difficulty or a serious infusion reaction requires prompt care. Early skin management can reduce complications and treatment interruption.
Immune-related inflammation can affect almost any organ and may arise after treatment ends. New or worsening diarrhoea, breathlessness, jaundice, severe fatigue, headache, visual change, muscle weakness, confusion or major changes in thirst or urination should be reported immediately.
Urgent warning signs include increasing abdominal pain, fever, jaundice, breathlessness, persistent vomiting, heavy wound drainage, bleeding, confusion, a rapidly enlarging abdomen or inability to eat or drink. Post-hepatectomy liver failure, bile leak, infection, bleeding and thrombosis require early recognition.
Some pain, fatigue or fever may be expected, but persistent high fever, worsening pain, jaundice, shortness of breath, black stools, vomiting blood or neurological changes need urgent review. The treating centre should define the normal recovery pattern and concerning warning signs.
Supportive care is not limited to the last stage of illness. It can be delivered alongside surgery, chemotherapy, immunotherapy and local liver treatment.
Assessment may address:
Prehabilitation may combine nutrition, exercise, smoking cessation, breathing exercises and management of comorbidity. It should be tailored to the patient’s condition rather than prescribed as a generic fitness programme.
Palliative-care specialists can help with symptoms and decision-making at any stage. Their involvement does not mean that anticancer treatment has stopped.
A high-quality international pathway begins before the patient books a flight. The objective is to determine what is known, what is missing, whether travel could change care and which specialist team is appropriate.
Prepare a concise timeline and gather pathology, imaging, treatment and biomarker material. Original DICOM images are essential for a genuine resectability opinion.
Useful questions include:
The case may need a hepatobiliary surgeon, colorectal surgeon, gastrointestinal medical oncologist, interventional radiologist and radiation oncologist rather than a single general opinion. A hospital brand alone does not establish that the required expertise is available to review the case.
Relevant Recmed profiles include hepatobiliary surgeon Prof. Dr. Koray Karabulut, colorectal surgeon Prof. Dr. Oktar Asoglu, colorectal surgeon Prof. Dr. Emre Sivrikoz and medical oncologist Prof. Dr. Mutlu Demiray. A profile link is not a treatment recommendation; suitability depends on the individual case, hospital resources and availability.
The written opinion should state:
The estimate should be tied to the medical plan. A low figure that excludes surgeon fees, devices, pathology, medicines, intensive care or management of complications is not directly comparable with an inclusive estimate.
The Turkish team and home oncologist should agree on timing, anticoagulation, medicine supply, wound or drain care, blood tests, imaging and urgent contact arrangements. Travel should not interrupt time-sensitive cancer treatment without a defined reason.
Recmed’s Cancer Treatment in Türkiye patient guide provides a broader overview of planning oncology care abroad.
Send the most complete available set, with translations where requested:
For radiology, include the study dates and specify which scan occurred before, during and after systemic treatment. The team needs to identify original lesion locations and response over time.
For pathology, do not ship irreplaceable blocks or slides until the receiving institution confirms the address, customs requirements, tracking method and return policy.
Before agreeing to treatment, ask:
There is no single price for treatment of colorectal cancer with liver metastases. Cost depends on the actual clinical plan.
Important factors include:
A written estimate should state:
The lowest quoted amount is not necessarily the lowest final cost. Compare equivalent medical plans and included services.
Patients travelling from African countries should be treated as individuals, not as one market. Medicine registration, local supply, insurance and medical-aid rules, imaging access and oncology services vary substantially between countries and cities.
A remote review before travel can help determine:
The home oncology team should remain involved whenever possible. A high-quality international plan does not assume that all care must move abroad. It defines the parts that require specialist expertise and preserves continuity close to home.
Patients should also verify:
No coordinator or hospital should guarantee a visa, medicine supply, procedure acceptance, price or clinical outcome before the responsible team has completed its assessment.
Fitness to fly depends on the procedure, recovery, anaemia, infection risk, pain control, thrombosis risk, oxygen needs and the patient’s ability to mobilise and maintain hydration.
After major liver or colorectal surgery, patients may need to remain near the treating hospital for review and possible drain, wound or stoma care. Flying too early can complicate recognition and treatment of bleeding, bile leak, infection, bowel problems or thrombosis.
Before departure, the patient should receive:
Before systemic treatment continues at home, the overseas and home teams should confirm the exact generic medicines, doses, schedule, supportive medicines, monitoring and criteria for dose delay. Brand availability may differ.
Recmed Medical Travel provides medical-travel coordination. Depending on the patient’s needs, support may include:
Recmed does not diagnose cancer, prescribe medicines, determine resectability or replace a licensed medical team. Clinical decisions are made by the responsible physicians and hospitals after reviewing the full case. Recmed cannot ethically guarantee acceptance, a particular operation, cure, survival, price, visa approval or outcome.
No. It remains colorectal cancer because the cells originated in the colon or rectum. It may be called colorectal liver metastases, liver secondaries or secondary cancer in the liver.
Yes, a confirmed distant liver metastasis is stage IV disease. However, stage IV includes very different situations. Selected liver-limited cases may still be treated with curative intent.
Some carefully selected patients achieve long-term disease-free survival after complete local treatment, but recurrence is common and cure cannot be promised. The appropriate phrase is curative-intent treatment.
All important disease must be removable or destroyable while preserving enough functioning liver with adequate blood inflow, venous outflow and biliary drainage. Disease biology, extrahepatic spread and patient fitness also matter.
There is no universal number. Distribution, relation to vessels and bile ducts, future liver remnant, extrahepatic disease and the ability to clear every lesion are more important than lesion count alone.
Yes, conversion treatment can make some initially unresectable cases suitable for surgery or ablation. Imaging and multidisciplinary reassessment should occur at a defined interval so that an operative opportunity is not missed.
For technically suitable colorectal liver metastases under 3 cm, current randomised evidence and ESMO guidance support thermal ablation as a curative-intent option and may favour it over resection. This cannot be generalised to larger or unsafe lesions, and expert selection remains essential.
Both use heat to destroy a tumour. Microwave ablation can create heat more rapidly and may be less affected by nearby blood flow; radiofrequency ablation has a longer-established evidence base. Location, size, equipment and operator experience guide the choice.
Yes. A surgeon may remove larger or difficult lesions and ablate small lesions elsewhere, allowing complete treatment while preserving more healthy liver tissue.
Sometimes. Simultaneous surgery can suit a fit patient with a straightforward bowel operation and limited liver treatment. Complex rectal surgery or major hepatectomy is more often staged. Symptoms and disease biology determine the sequence.
Liver MRI can find or characterise small lesions and map their relation to liver structures more precisely. It is particularly valuable before surgery or ablation and after chemotherapy has changed lesion visibility.
Every colorectal cancer should undergo validated MMR/MSI assessment. In metastatic disease, extended RAS and BRAF V600E are also central. HER2 and selected broader NGS findings may matter. The required tests depend on the clinical setting and available treatment.
Immune-checkpoint therapy is a first-line standard for unresectable or metastatic MSI-H or dMMR colorectal cancer. Current options and approvals vary by country. It is not routinely effective for most microsatellite-stable colorectal cancers outside a validated indication or trial.
The case is reassessed. Selected patients can have repeat resection, ablation, SBRT or another local treatment; others receive systemic treatment or enter a clinical trial.
It is an evidence-based curative-intent option for a very small subgroup with permanently unresectable, liver-only disease and favourable biology. Eligibility is strict, access is programme- and policy-dependent, and lifelong immunosuppression is required.
Often, yes. A meaningful review usually requires pathology, a treatment timeline, biomarker results and original CT or MRI images in DICOM format. The team may still require an in-person examination or additional tests before confirming treatment.
If you are considering a specialist review in Türkiye, begin with the records rather than booking treatment by name. The first objective is to determine whether the diagnosis and staging are complete, whether all imaging has been reviewed by the appropriate specialists and whether the case is resectable, potentially resectable or best managed with another strategy.
A complete, organised file helps the clinical team give a more precise opinion and reduces avoidable delays. The result of the review may support surgery, ablation, systemic treatment, further testing, care in the patient’s home country or a different plan altogether.
This material is for general education and does not provide a diagnosis, individual medical advice or a treatment recommendation. Eligibility for surgery, ablation, radiotherapy, transplantation, immunotherapy or any medicine can be determined only by licensed clinicians after reviewing complete medical records and the patient’s current condition.
Medicine approvals, guidelines, reimbursement and availability vary between countries and can change. Do not start, stop or change cancer treatment on the basis of an online article. Patients with urgent or rapidly worsening symptoms should seek immediate medical help where they are.
Publication date: 22 November 2026. Medical review should be completed by a licensed gastrointestinal oncologist and hepatobiliary surgeon before publication, with the reviewer names and next review date displayed on the page.